Isis Pharmaceuticals
Executive Summary
Oligonucleotide-based drug company announces $17.7 mil. private placement at $6.50 per share Nov. 24. Proceeds will be used for product R&D and general company purposes. Closing of the offering is contingent on a registration statement regarding resales by purchasers.